Article Text

other Versions

PDF

Correspondence
Vitamin D and lung function
  1. R P Young1,2,
  2. R J Hopkins2
  1. 1School of Biological Sciences, University of Auckland, Auckland, New Zealand
  2. 2Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
  1. Correspondence to Dr Robert P Young, Respiratory Genetics Group, PO Box 26161, Epsom, Auckland 1344, New Zealand; roberty{at}adhb.govt.nz

Statistics from Altmetric.com

Afzal et al1 recently reported that low plasma 25-hydroxyvitamin D is associated with a decline in lung function and chronic obstructive pulmonary disease (COPD). While this finding persisted after adjustment for possible confounding variables, and concurs with the findings of others,2 we believe it might still be spurious.

First, we suggest the association between plasma vitamin D and lung function is subject to a threshold effect, evident in both the cross-sectional data (figures 1 and 3, reference 1) and prospective data (figure 2 and table 2—see our figure 1 below), and primarily limited to the lowest two quintiles (ie, only for the 1st–2nd quintiles can a relationship be consistently identified). By contrast, for the 3rd–5th quintiles, which roughly correspond to normal vitamin D levels (>50 nmol/L), the relationship between vitamin D levels and lung function is no longer apparent (ie, flattens in figures 1, S1 and S2 or fails to significantly diverge in figures 2, 3, 4, S3 and S4, with overlapping CIs, reference 1). The presence of a threshold effect is critically important as ‘adjustment’ for relevant confounding variables (eg, smoking dose, age and height) assumes a linear relationship, not a threshold effect where stratification to match for potential confounding variables better identifies confounding or mediating effects. Interestingly, the relationship evident for lung function decline in the 1st–2nd vitamin D quintiles (figure 2) is all but lost in the sensitivity analysis (after adjustment for height and gender, figure S3).1 Second, we are also concerned that the vitamin D association with FEV1%predicted is consistently mirrored for FVC%predicted (see published figures and our figure below), but has no effect on the FEV1/FVC ratio (ie, cornerstone of the COPD definition).1 ,2 This global reduction in lung function could be explained by the mediating/confounding effects of one or a combination of reduced physical performance (frailty)3 or increased systemic inflammation,4 both of which correlate with low vitamin D levels (<50 nmol/L) in older adults.3 ,4 In a recently reported prospective population study, increased systemic inflammation was associated with greater declines in lung function.5 Given the effect of low vitamin D on lung function decline is sensitive to smoking status (see our figure 1 below), it is difficult to simply link vitamin D level with COPD.

Figure 1

Decline in lung function according to smoking status and quintile of vitamin D level in a prospective cohort.

These observations suggest to us that despite the excellent study design of the Danish study1 (large sample size, comparable validating cohort, prospective data and statistically significant differences), further analysis (including c-reactive protein (CRP) levels) is required to better understand the role of vitamin D status in COPD.

References

View Abstract

Footnotes

  • Correspondence submitted in relation to: Afzal S, Lange P, Bojesen SE, et al. Plasma 25-hydroxyvitamin D, lung function and risk of chronic obstructive pulmonary disease. Thorax 2014;69:24–31.

  • Contributors RPY conceived of the idea, researched the literature and wrote the first draft, edited all drafts and approved the final version of this correspondence. RJH researched the literature, edited all drafts and approved the final version of this correspondence.

  • Competing interests RPY, and the funding of his research, has been supported by grants from the University of Auckland, Auckland District Health Board, Auckland Medical Research Foundation, Health Research Council of New Zealand, Lotteries Health and Synergenz BioSciences Ltd. Synergenz BioSciences Ltd holds patents for gene-based risk testing for lung cancer susceptibility.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles